Correction: TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas
Jiabo Li(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Xuejun Yang(Dali University), Luqing Tong(Johns Hopkins University), Xiude Ren(Tianjin Medical University General Hospital), Jikang Fan(Tianjin Medical University General Hospital), Haolang Ming(Tianjin Medical University General Hospital), Xiao Ren(Tianjin Medical University General Hospital), Guanjie Shang(Tianjin Medical University General Hospital), Jun Dong(TEDA International Cardiovascular Hospital), Chen Zhang(Tianjin Medical University General Hospital), Tao Li(Army Medical University), Xuya Wang(Tianjin Medical University General Hospital), Lei Chen(Zhuzhou Central Hospital), Yiming Zhang(Shandong University of Traditional Chinese Medicine), Hao Zhang(Northwestern Polytechnical University), Lulu Chen(Zunyi Medical University), Yi Li(Peking University), Jie Liu(Ministry of Education), Xiaoguang Fan(Northwestern Polytechnical University), Jinhao Zhang(Southwest Medical University), Qiang Huang(Ministry of Education of the People's Republic of China), Shengping Yu(Tianjin Medical University General Hospital), Jinzhang Sun(Tianjin Medical University General Hospital)
Cited by 2
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Geometric Interpretation of Gene Coexpression Network Analysis
|PLoS Computational Biology|2008|922
Glioma targeted therapy: insight into future of molecular approaches
|Molecular Cancer|2022|727